# US 2019/0317091 A1 · Method of early diagnosis of immune-mediated inflammatory disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0317091 A1
- Document ID: US20190317091A1
- Status: Published application
- Kind: A1
- Application number: 16/314,654
- Filed: 2017-06-23
- Published: 2019-10-17
- Earliest claimed: 2016-07-02
- Assignees: Universite De Liege; Centre Hospitalier Universitaire De Liege
- Applicants: Universite De Liege; Centre Hospitalier Universitaire De Liege
- Inventors: Michel MALAISE; Dominique DE SENY
- Web page: https://patentgrep.com/patent/US20190317091A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 2800/105: Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

An in-vitro method for early diagnosing or prediction of immune-mediated inflammatory diseases, comprising: —obtaining a sample from a subject; —quantifying simultaneously by one LC/MS-MS analysis of said sample, a presence of V65 vitronectin fragment or fragment, variant or degradation product thereof; and a presence of a complement C3f or fragment or variant or degradation products thereof;

## Claims

### Claim 1

An in-vitro method for early diagnosing or prediction of immune-mediated inflammatory diseases, comprising:
obtaining a biological sample from a subject;
quantifying simultaneously by one LC/MS-MS analysis of said biological sample, a presence of V65 vitronectin fragment or fragment, variant or degradation product thereof; and a presence of a complement C3f or fragment, variant or degradation product thereof;

### Claim 2 (depends on 1)

The method according to claim 1 wherein the subject is a human;

### Claim 3 (depends on 1, 2)

The Method according to claim 1 or 2 wherein the biological sample is blood, serum, plasma, urine, or synovial fluid;

### Claim 4

The method according to any preceding claims, wherein the V65 vitronectin fragment comprises the following amino sequence: 381SQRGHSRGRNQNSRRPS397

### Claim 5

The method according to any preceding claims wherein the complement C3f comprises the following amino sequence: 1304SSKITHRIHWESASLLR1320

### Claim 6

The method according to any preceding claims wherein the immune-mediated inflammatory diseases is osteoarthritis.

### Claim 7

The method according to any preceding claims wherein the immune-mediated inflammatory diseases is lupus

### Claim 8

The method according to any preceding claims wherein the immune-mediated inflammatory diseases is sclerodermia

### Claim 9

The method according to any preceding claims wherein the LC/MS-MS analysis is a microfluidic liquid chromatography coupled to a nanoelectrospray source ion trap mass spectrometry analysis.

### Claim 10

The method according to any preceding claims comprising the following steps:
mixing the biological sample with an acidic aqueous solution;
loading the resulting mixture on a trapping LC column;
optionally washing the column to remove uncertain component;
eluting the column with an alcoholic mixture and obtaining an eluate;
drying the eluate;
dispersing the dried eluate in an acetonitrile aqueous solution;
loading the resulting dispersion on a reversed phase LC column and separating two mobile phase A and B;
injecting by continuous flux in MS-MS, both phases A and B and quantifying V65 vitronectin fragment or fragment, variant or degradation product thereof simultaneously to quantificating complement C3f or fragment, variant or degradation product thereof.

### Claim 11 (depends on 10)

The method according to claim 10 wherein the acidic aqueous solution comprise trifluoro acetic acid (TFA).

### Claim 12 (depends on 11)

The method according to claim 11 wherein the acidic aqueous solution comprise 1% v trifluoro acetic acid (TFA).

### Claim 13 (depends on 10, 11, 12)

The method according to anyone of claims 10 to 12 wherein the alcoholic mixture is methanol/water/TFA.

### Claim 14 (depends on 13)

The method according to claim 13 wherein the mixture methanol/water/TFA is in the ratio from 90:7:3 to 90:9:1 v/v/v, preferably 90:9:1 v/v/v.

### Claim 15 (depends on 10, 11, 12, 13, 14)

The method according to anyone of claims 10 to 14 wherein the acetonitrile aqueous solution comprises TFA

### Claim 16 (depends on 15)

The method according to claim 15 wherein the acetonitrile aqueous solution comprising TFA in the ratio acetonitrile/water/TFA from 3:97:0.1 to 1:99:0.1 v/v/v preferably 1:99:0.1 v/v/v.

### Claim 17

The method according to any preceding claims wherein C3f or fragment, variant or degradation product thereof are quantified at m/z 459.3, 530.7 and 646.3 and wherein V65 vitronectin fragment or fragment, variant or degradation product thereof are quantified at m/z 434.9, 445.2, 460.5, 466.2, 469.7, 480.3, 485.3.
